Author: Lucy J. Sannes, PhD, MBA

TABLES
Table 2.1. Selected Nucleic Acid Amplification Technologies and Selected Companies that Use These Technologies
Table 2.2. Selected Examples of Companies with Proprietary Microarray or Other Multiplex Technology: Moving Beyond Multiplex PCR Assays
Table 3.1. Selected Companies Developing and/or Marketing Molecular Diagnostic Tests for Oncology (Both Solid Tumors and Hematological Cancers): Risk, Diagnostic, Prognostic, and Personalized Medicine Tests
Table 3.2. Selected Companies Developing and/or Marketing Molecular Personalized Medicine Tests; Pharmacogenomics and Companion Diagnostics: Moving Beyond Oncology
Table 3.3. Selected Companies Developing and/or Marketing Molecular Diagnostic Tests for Inherited Disease or Prenatal Diagnosis
Table 3.4. Selected Companies Developing and/or Marketing Molecular Tests for Prediction of Disease Risk
Table 3.5. Other Selected Companies Developing and/or Marketing Molecular Diagnostic Tests
Table 4.1. Selected Recent Corporate Acquisitions in Molecular Diagnostics
Table 4.2. Valid Genomic Biomarkers in the Context of Approved Drug Labels